| Literature DB >> 17052763 |
Kazuya Shirato1, Hidekazu Nishimura, Masayuki Saijo, Michiko Okamoto, Masahiro Noda, Masato Tashiro, Fumihiro Taguchi.
Abstract
Human respiratory syncytial virus (RSV) is a major causative agent of lower respiratory tract infections in children and the elderly. A reverse transcription-loop-mediated isothermal amplification (RT-LAMP) was developed assay to amplify the genome of RSV subgroups A and B, in order to improve current diagnostic methods for RSV infection. The primer sets for RT-LAMP were designed using highly conserved nucleotide sequences in the matrix protein region of subgroups A and B, and were specific for each subgroup. The RT-LAMP efficiency was compared to virus isolation and a commercially available enzyme immunoassay (EIA) for RSV detection (BD Directigen EZ RSV test), using nasopharyngeal aspirates from 59 children with respiratory tract infections. The RT-LAMP was specific for RSV and could not detect other respiratory pathogens. 61% (36/59) of children were positive by RT-LAMP, 34% (20/59) by viral isolation, and 56% (26/46) by EZ RSV. Of 16 specimens that were negative by both antigen detection and virus isolation, 12.5% (2/16) were RT-LAMP positive. These results suggest that the RT-LAMP is more sensitive than other methods used to detect RSV. The RT-LAMP assay developed in this study may be useful for diagnostic and epidemiological studies of RSV infection.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17052763 PMCID: PMC7112771 DOI: 10.1016/j.jviromet.2006.09.014
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014
Primer sets used in the RT-LAMP assay
| Primer | Position | Sequence (5′–3′) |
|---|---|---|
| Primer set A | ||
| RSAM-F3 | 3224–3246 | GGGGCAAATATGGAAACATACGT |
| RSAM-B3 | 3438–3421 | GAAGGTCCATTGGGTGTG |
| RSAM-FIP (Flc + F2) | 3319–3296 + 3255–3272 | AGGGTCATCGTCTTTTTCTAAGACAttttTTCACGAAGGCTCCACAT |
| RSAM-BIP (Blc + B2) | 3322–3343 + 3404–3382 | ATCACTTACAATATGGGTGCCCttttGTATGTTGACATTAGCTAGTTCT |
| RSAM-Loop F | 3295–3273 | TTGTATTGAACAGCAGCTGTGT |
| RSAM-Loop B | 3359–3379 | ATGCCAGCAGATTTACTTATA |
| Primer set B | ||
| RSBM-F3 | 3254–3275 | GGGCAAATATGGAAACATACG |
| RSBM-B3 | 3462–3445 | CCTTTGGGCGTAGAGATC |
| RSBM-FIP (Flc + F2) | 3360–3336 + 3276–3294 | GTTAGTGATGCAGGATCATCATCTTttttTGAACAAGCTTCACGAAGG |
| RSBM-BIP (Blc + B2) | 3363–3383 + 3443–3422 | TATGGGTGCCTATGTTCCAGTttttGCTTCACTAGTATGTTGATGCT |
| RSBM-Loop F | 3322–3301 | GTACTGAACAGCTGCTGTGTAT |
| RSBM-Loop B | 3395–3419 | GCAGACTTGCTCATAAAAGAACTTG |
RSV subgroup A virus, GenBank accession No. NC_001803; subgroup B virus, NC_001781.
Fig. 1Location of the RT-LAMP primer region. RT-LAMP primer sets were designed using PrimerExplorer online software. The position of six essential primers (F3, F2, F1, B1, B2, and B3) and the loop primer regions are shown by lines and bold font. Underlined sequences illustrate the recognition site of each restriction enzyme (CATG of NlaIII and ACATGT of XbaI).
Specificity of the RT-LAMP assay
| Pathogen | Strain | Primer set | |
|---|---|---|---|
| Subgroup A | Subgroup B | ||
| RNA viruses | |||
| Respiratory syncytial virus | long (A) | 13.7 ± 0.5 | >45.0 |
| CH-18537 (B) | >45.0 | 20.2 ± 0.2 | |
| Viruses isolated from clinical samples | N96-77 (A) | 17.8 ± 0.5 | >45.0 |
| N97-23 (A) | 20.1 ± 0.7 | >45.0 | |
| N91-730(B) | >45.0 | 15.4 ± 0.4 | |
| N96-51 (B) | >45.0 | 14.2 ± 0.7 | |
| N96-728 (B) | >45.0 | 14.6 ± 0.9 | |
| Metapneumovirus | 2003–2404 | >45.0 | >45.0 |
| Human coronavirus | NL63 | >45.0 | >45.0 |
| 229E | >45.0 | >45.0 | |
| SARS coronavirus | Frankfurt | >45.0 | >45.0 |
| Parainfluenza virus 3 | C-245 | >45.0 | >45.0 |
| Influenza virus | A/VN/JP1203/04 H5N1 | >45.0 | >45.0 |
| A/Panama/2007/97 H3N2 | >45.0 | >45.0 | |
| A/NC H1N1 | >45.0 | >45.0 | |
| B/Shanghai/361/2002 | >45.0 | >45.0 | |
| DNA virus | |||
| Adenovirus | Type 3 (O.B.) | >45.0 | >45.0 |
| Type 4 (R163) | >45.0 | >45.0 | |
| Type 7 (Gomen) | >45.0 | >45.0 | |
| Bacteria | |||
| Bordetella pertussis | Tohama | >45.0 | >45.0 |
| Bordetella parapertussis | ATCC15311 | >45.0 | >45.0 |
| Haemophils influenza (biotype 3) | >45.0 | >45.0 | |
| Haemophils parainfluenza (biotype 1) | >45.0 | >45.0 | |
| Mycoplasma pneumonia | M129 | >45.0 | >45.0 |
Time of positivity in minutes.
Sensitivity of the RT-LAMP assay
| PFU (log) | 3 | 2 | 1 | 0 | −1 | −2 | −3 |
|---|---|---|---|---|---|---|---|
| Lot l | |||||||
| Long | 13.4 | 15.1 | 16.3 | 18.5 | 24.7 | 28.0 | >45 |
| CH-18537 | 14.6 | 17.9 | 18.9 | 24.0 | 33.8 | >45 | >45 |
| Lot 2 | |||||||
| Long | 15.7 | 17.2 | 18.8 | 22.2 | 23.9 | 34.3 | >45 |
| CH-18537 | 14.1 | 15.3 | 17.3 | 20.0 | 29.3 | 39.6 | >45 |
| Lot 3 | |||||||
| Long | 21.8 | 24.4 | 27 | 29.7 | 42.3 | >45 | >45 |
| CH-18537 | 12.7 | 13.9 | 16.5 | 18.5 | 22.9 | 32.5 | >45 |
Time of positivity in minutes.
Success rate of RSV detection in clinical nasopharyngeal aspirates
| Number of tested specimens | RSV positive | RSV negative | Percent of positive | |
|---|---|---|---|---|
| RSV isolation | 59 | 20 | 39 | 34% (20/59) |
| EZ RSV | 46 | 26 | 20 | 57% (26/46) |
| RT-PCR | 59 | 34 | 25 | 58% (34/59) |
| RT-LAMP | 59 | 36 | 23 | 61% (36/59) |
Ability of EZ RSV, RSV isolation, and the RT-LAMP assay to detect RSV detection from clinical specimens
| RT-PCR | RT-LAMP assay | |||
|---|---|---|---|---|
| Positive | Negative | Positive | Negative | |
| RSV isolation positive ( | 20 | 0 | 20 | 0 |
| EZ RSV positive ( | 16 | 0 | 16 | 0 |
| EZ RSV negative ( | 4 | 0 | 4 | 0 |
| RSV isolation negative ( | 9 | 17 | 11 | 15 |
| EZ RSV positive ( | 9 | 1 | 9 | 1 |
| EZ RSV negative ( | 0 | 16 | 2 | 14 |